CA 19-9 anticorps

N° du produit ABIN6296794

Cet anticorps Souris Monoclonal détecte spécifiquement CA 19-9 dans IHC, FACS et IF. Il présente une réactivité envers Humain.

Aperçu rapide pour CA 19-9 anticorps (ABIN6296794)

Antigène: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CA 19-9 est non-conjugé

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF)

Détail du produit anti-CA 19-9 anticorps

Fonction: Mouse anti-Human CA19-9 Antibody [Sodium Azide Free]

Specificité: Cytoplasmic

Purification: Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Immunogène: Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Information d'application

Indications d'application: Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2)

Restrictions: For Research Use only

Stockage

Buffer: In 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.

Détails sur CA 19-9

Antigène: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Autre désignation: CA19-9

Sujet:

Target Description: CA19-9, a carbohydrate epitope expressed on a high MW (>400 kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.